An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Inclusion Criteria: * Clinically confirmed diagnosis of active atopic dermatitis (AD), according to the revised Hanifin and Rajka criteria * 12-month history of AD and had no significant flares in AD for at least 4 weeks before screening * inadequate response to a ≥1 month treatment with topical medications * Atopic dermatitis covering ≥10% of the body surface area * EASI score ≥16 * Validated Investigator Global Assessment (VIGA) ≥3 * Use of emollient(s) at least 2x daily for 1 week prior to baseline * Negative coronavirus disease (COVID)-19 results at screening Exclusion Criteria: * Uncontrolled moderate-to-severe asthma * Uncontrolled diabetes * Stage III or IV cardiac failure * Severe renal condition * Major surgery within 8 weeks of screening * Immunodeficiency and/or receipt of immunosuppressive drugs within 4 weeks of baseline * Use of systemic Janus kinase (JAK) inhibitor within 8 weeks of baseline * Received live or live-attenuated vaccine within 4 weeks of baseline * Prior receipt of RPT193